Financials Tissue Regenix Group plc
Equities
TRX
GB00BNTXR104
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.5 GBX | 0.00% | 0.00% | +18.27% |
Mar. 19 | Tissue Regenix annual loss narrows sharply as revenue jumps | AN |
Mar. 19 | Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 11.56 | 37.89 | 37.54 | 39.66 | 36.61 | 43.3 | - |
Enterprise Value (EV) 1 | 11.46 | 31.13 | 35.07 | 39.91 | 37.66 | 45.92 | 47.14 |
P/E ratio | -1.67 x | -2.45 x | -9.91 x | -17.1 x | -27.2 x | -366 x | 147 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 0.89 x | 2.95 x | 2.48 x | 1.99 x | 1.58 x | 1.6 x | 1.4 x |
EV / Revenue | 0.88 x | 2.43 x | 2.32 x | 2 x | 1.62 x | 1.69 x | 1.52 x |
EV / EBITDA | -1.87 x | -12.2 x | -15.2 x | -56 x | 51.8 x | 29.1 x | 18.8 x |
EV / FCF | -1.61 x | -4.29 x | -8 x | -29.1 x | 76.4 x | -128 x | -38.7 x |
FCF Yield | -62.1% | -23.3% | -12.5% | -3.44% | 1.31% | -0.78% | -2.58% |
Price to Book | - | - | - | 1.53 x | 1.54 x | 1.85 x | 1.81 x |
Nbr of stocks (in thousands) | 11,559 | 70,170 | 70,170 | 70,197 | 70,413 | 70,413 | - |
Reference price 2 | 1.000 | 0.5400 | 0.5350 | 0.5650 | 0.5200 | 0.6150 | 0.6150 |
Announcement Date | 6/5/20 | 4/28/21 | 3/15/22 | 3/21/23 | 3/19/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 13.03 | 12.83 | 15.12 | 19.95 | 23.18 | 27.11 | 31.03 |
EBITDA 1 | -6.133 | -2.553 | -2.302 | -0.7131 | 0.7271 | 1.576 | 2.512 |
EBIT 1 | -7.179 | -3.315 | -3.138 | -1.638 | -0.3097 | 0.862 | 1.736 |
Operating Margin | -55.08% | -25.84% | -20.75% | -8.21% | -1.34% | 3.18% | 5.6% |
Earnings before Tax (EBT) 1 | -7.66 | -10.24 | -3.937 | -2.305 | -1.312 | 0.0635 | 0.9785 |
Net income 1 | - | -9.709 | -3.669 | -2.196 | -1.347 | -0.2325 | 0.461 |
Net margin | - | -75.68% | -24.27% | -11.01% | -5.81% | -0.86% | 1.49% |
EPS 2 | -0.6000 | -0.2200 | -0.0540 | -0.0330 | -0.0191 | -0.001680 | 0.004180 |
Free Cash Flow 1 | -7.12 | -7.251 | -4.384 | -1.374 | 0.4929 | -0.3585 | -1.217 |
FCF margin | -54.63% | -56.52% | -29% | -6.89% | 2.13% | -1.32% | -3.92% |
FCF Conversion (EBITDA) | - | - | - | - | 67.78% | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 6/5/20 | 4/28/21 | 3/15/22 | 3/21/23 | 3/19/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 0.25 | 1.05 | 2.62 | 3.84 |
Net Cash position 1 | 0.09 | 6.76 | 2.48 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | -0.3554 x | 1.443 x | 1.663 x | 1.528 x |
Free Cash Flow 1 | -7.12 | -7.25 | -4.38 | -1.37 | 0.49 | -0.36 | -1.22 |
ROE (net income / shareholders' equity) | - | - | - | -8.22% | -5.58% | 0.1% | 2.4% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | 0.3700 | 0.3400 | 0.3300 | 0.3400 |
Cash Flow per Share 2 | -0.5700 | - | - | - | 0.0100 | 0 | 0.0200 |
Capex 1 | 0.44 | 1.37 | 1.18 | 0.31 | 0.32 | 0.91 | 2.84 |
Capex / Sales | 3.36% | 10.7% | 7.82% | 1.57% | 1.4% | 3.34% | 9.14% |
Announcement Date | 6/5/20 | 4/28/21 | 3/15/22 | 3/21/23 | 3/19/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.27% | 53.94M | |
+4.36% | 32.47B | |
+14.14% | 7.45B | |
+22.93% | 3.89B | |
-16.29% | 3.15B | |
-25.96% | 1.28B | |
-36.14% | 1.09B | |
-35.42% | 902M | |
-0.13% | 893M | |
-24.12% | 857M |
- Stock Market
- Equities
- TRX Stock
- Financials Tissue Regenix Group plc